Overview

A Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone Injection in Patients With Prader-Willi Syndrome

Status:
Unknown status

Trial end date:
2020-01-01

Target enrollment:

Participant gender:

Summary

To evaluate the effectiveness of rhGH (Recombinant human growth hormone) injection for improving motor development in patients with PWS.

Phase:

Phase 3

Details

Lead Sponsor:

GeneScience Pharmaceuticals Co., Ltd.

Collaborators:

Beijing Children's Hospital
Children's Hospital of Fudan University
Peking Union Medical College Hospital
Peking University First Hospital
The Children's Hospital of Zhejiang University School of Medicine
Tongji medical college huazhong university of science & technology

Treatments:

Hormones